kidney cancer | GenomeWeb

kidney cancer

This Week in PLOS

In PLOS this week: Kashmiri ancestry analysis, genome-wide association study of gestational age, and more.

A renal cell carcinoma study revealed increased metabolic gene expression in PD-L1-positive tumors from individuals who did not respond to nivolumab.

The company plans to launch its first bladder cancer test in the second half of the year, and is in the early stages of validating a third test for prostate cancer.

Both institutions aim to develop novel liquid biopsy approaches that would improve physicians' ability to diagnose, monitor, and treat cancer patients. 

A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.

Researchers and clinicians attempting to select targeted therapies must take sample heterogeneity into account.

Members of TCGA characterized papillary renal cell carcinomas, uncovering two main tumor groups and several more prognostically informative subtypes.

NEW YORK (GenomeWeb) — Rosetta Genomics said today that it has received final approval from the New York State Department of Health for use of its Rosetta Kidney Cancer Test on patient samples from the state.

NEW YORK (GenomeWeb) – Fluxion Biosciences said today that it will collaborate with the Stanford University School of Medicine on developing molecular diagnostic tests to identify circulating tumor cells.

NEW YORK (GenomeWeb News) – 20/20 GeneSystems said on Monday it was awarded a $750,000 contract by the National Cancer Institute to develop a test for predicting which patients with advanced stage kidney cancer may benefit from anti-angiogenic therapy.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.